Skip to main content
Top
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Breast Cancer | Research article

Breast cancer care in northern Ethiopia – cross-sectional analysis

Authors: Biniyam Tefera Deressa, Nikola Cihoric, Eugenia Vlaskou Badra, Alexandros Tsikkinis, Daniel Rauch

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

In Ethiopia, the incidence of new cases of breast cancer is currently increasing resulting to high rates of morbidity and mortality. Breast cancer is by far the most common cancer accounting for more than one out of three cancer cases in women and one out of every five in the general population. The study was conducted in University of Gondar Hospital cancer center, located in the North-West Ethiopia; to evaluate the clino-pathologic characteristics of breast cancer and care provided for patients.

Methods

All biopsy proven breast cancer patients treated between 2016 and 2017, were identified and information regarding histology, stage, therapeutic procedure and follow up was retrospectively collected from their individual medical records and descriptive analysis was done.

Results

Among 82 patients treated, 67 (82%) were women and 15 (18%) were men. The median age at the time of diagnosis was 45 years (25–82 years). Operation was performed for 56 (68%) patients. The predominant histology was ductal carcinoma in 61 patients (74%), followed by breast carcinoma of No Special Type (NST) in 17 (21%). The late presentation of the patients and the advanced stage at the time of presentation was observed in most of the patients. Chemotherapy was administered in 79 (96%) patients. Radiotherapy was not available in the hospital.

Conclusion

Breast cancer incidence is rising and becoming a major public health problem in Northern Ethiopia. Breast cancer care in northern-Ethiopia is limited in terms of both pathology, imaging and the offered treatment modalities, which need to be improved.
Literature
1.
go back to reference Torre LA, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRef Torre LA, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRef
2.
go back to reference Timotewos G, et al. First data from a population based cancer registry in Ethiopia. Cancer Epidemiol. 2018;53:93–8.CrossRef Timotewos G, et al. First data from a population based cancer registry in Ethiopia. Cancer Epidemiol. 2018;53:93–8.CrossRef
3.
go back to reference Lukong KE, Ogunbolude Y, Kamdem JP. Breast cancer in Africa: prevalence, treatment options, herbal medicines, and socioeconomic determinants. Breast Cancer Res Treat. 2017;166(2):351–65.CrossRef Lukong KE, Ogunbolude Y, Kamdem JP. Breast cancer in Africa: prevalence, treatment options, herbal medicines, and socioeconomic determinants. Breast Cancer Res Treat. 2017;166(2):351–65.CrossRef
4.
go back to reference Abate Y, et al. Trends of breast cancer in Ethiopia. Int J Cancer Res Mol Mech. 2016;2:1–5. Abate Y, et al. Trends of breast cancer in Ethiopia. Int J Cancer Res Mol Mech. 2016;2:1–5.
5.
go back to reference Memirie ST, et al. Estimates of Cancer incidence in Ethiopia in 2015 using population-based registry data. J Glob Oncol. 2018;4:1–11.CrossRef Memirie ST, et al. Estimates of Cancer incidence in Ethiopia in 2015 using population-based registry data. J Glob Oncol. 2018;4:1–11.CrossRef
6.
go back to reference Woldeamanuel YW, Girma B, Teklu AM. Cancer in Ethiopia. The Lancet Oncology. 2013;14(4):289–90.CrossRef Woldeamanuel YW, Girma B, Teklu AM. Cancer in Ethiopia. The Lancet Oncology. 2013;14(4):289–90.CrossRef
7.
go back to reference Kantelhardt EJ, et al. Cervical cancer in Ethiopia: survival of 1,059 patients who received oncologic therapy. Oncologist. 2014;19(7):727–34.CrossRef Kantelhardt EJ, et al. Cervical cancer in Ethiopia: survival of 1,059 patients who received oncologic therapy. Oncologist. 2014;19(7):727–34.CrossRef
8.
go back to reference Tigeneh W, et al. Pattern of cancer in Tikur Anbessa specialized hospital oncology center in Ethiopia from 1998 to 2010. Int J Cancer Res Mol Mech. 2015;1(1). Tigeneh W, et al. Pattern of cancer in Tikur Anbessa specialized hospital oncology center in Ethiopia from 1998 to 2010. Int J Cancer Res Mol Mech. 2015;1(1).
9.
go back to reference Ersumo T. Breast cancer in an Ethiopian population, Addis Ababa. East and Central African Journal of Surgery. 2006;11(1):81–6. Ersumo T. Breast cancer in an Ethiopian population, Addis Ababa. East and Central African Journal of Surgery. 2006;11(1):81–6.
10.
go back to reference pinkredribbon. Official launch of the Ethiopian National Cancer Control Plan. Pink ribbon/red ribbon; 2015. pinkredribbon. Official launch of the Ethiopian National Cancer Control Plan. Pink ribbon/red ribbon; 2015.
11.
go back to reference FMoH. National Cancer Control Plan, 2016-2020. International Cancer control partnership (ICCP); 2015. FMoH. National Cancer Control Plan, 2016-2020. International Cancer control partnership (ICCP); 2015.
12.
go back to reference Xuequan M. Ethiopia to set up 5 specialized cancer treatment centers XINHUANET; 2018. Xuequan M. Ethiopia to set up 5 specialized cancer treatment centers XINHUANET; 2018.
13.
go back to reference Diro E, et al. Long-term clinical outcomes in visceral Leishmaniasis/human immunodeficiency virus–Coinfected patients during and after Pentamidine secondary prophylaxis in Ethiopia: a single-arm clinical trial. Clin Infect Dis. 2018;66(3):444–51.CrossRef Diro E, et al. Long-term clinical outcomes in visceral Leishmaniasis/human immunodeficiency virus–Coinfected patients during and after Pentamidine secondary prophylaxis in Ethiopia: a single-arm clinical trial. Clin Infect Dis. 2018;66(3):444–51.CrossRef
14.
go back to reference Olende R. Phase III clinical study in Ethiopia launched to test two treatments for HIV-visceral Leishmaniasis co-infected patients. Drug for Neglected Disease initiative. 2014. Olende R. Phase III clinical study in Ethiopia launched to test two treatments for HIV-visceral Leishmaniasis co-infected patients. Drug for Neglected Disease initiative. 2014.
15.
go back to reference Deressa BT. A journey of a thousand miles begins with a single step: lessons from University of Gondar Cancer Center, Ethiopia. In: Golbal RT; 2017. Deressa BT. A journey of a thousand miles begins with a single step: lessons from University of Gondar Cancer Center, Ethiopia. In: Golbal RT; 2017.
16.
go back to reference Tefera B, et al. Patterns of Cancer in University of Gondar Hospital: north-West Ethiopia. J Oncol Med & Pract. 2016;1(106):2. Tefera B, et al. Patterns of Cancer in University of Gondar Hospital: north-West Ethiopia. J Oncol Med & Pract. 2016;1(106):2.
17.
go back to reference Edge SB. AJCC cancer staging manual, vol. 7: Springer; 2010. p. 97–100. Edge SB. AJCC cancer staging manual, vol. 7: Springer; 2010. p. 97–100.
18.
go back to reference Hadgu E, et al. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa. BMC Womens Health. 2018;18(1):40.CrossRef Hadgu E, et al. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa. BMC Womens Health. 2018;18(1):40.CrossRef
19.
go back to reference Kantelhardt EJ, et al. The prevalence of estrogen receptor-negative breast cancer in Ethiopia. BMC Cancer. 2014;14:895.CrossRef Kantelhardt EJ, et al. The prevalence of estrogen receptor-negative breast cancer in Ethiopia. BMC Cancer. 2014;14:895.CrossRef
20.
go back to reference Abate S, et al. Trends of breast cancer in Ethiopia. Int J Cancer Res Mol Mech. 2016;2(1). Abate S, et al. Trends of breast cancer in Ethiopia. Int J Cancer Res Mol Mech. 2016;2(1).
21.
go back to reference Anders CK, et al. Breast cancer before age 40 years. Semin Oncol. 2009;36(3):237–49.CrossRef Anders CK, et al. Breast cancer before age 40 years. Semin Oncol. 2009;36(3):237–49.CrossRef
22.
go back to reference Fredholm H, et al. Breast cancer in young women: poor survival despite intensive treatment. PLoS One. 2009;4(11):e7695.CrossRef Fredholm H, et al. Breast cancer in young women: poor survival despite intensive treatment. PLoS One. 2009;4(11):e7695.CrossRef
23.
go back to reference Akarolo-Anthony SN, Ogundiran TO, Adebamowo CA. Emerging breast cancer epidemic: evidence from Africa. Breast Cancer Res. 2010;12(Suppl 4):S8.CrossRef Akarolo-Anthony SN, Ogundiran TO, Adebamowo CA. Emerging breast cancer epidemic: evidence from Africa. Breast Cancer Res. 2010;12(Suppl 4):S8.CrossRef
24.
go back to reference Azim HA Jr, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res. 2014;16(4):427.CrossRef Azim HA Jr, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res. 2014;16(4):427.CrossRef
25.
go back to reference Gnerlich JL, et al. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg. 2009;208(3):341–7.CrossRef Gnerlich JL, et al. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg. 2009;208(3):341–7.CrossRef
26.
go back to reference Azim HA Jr, et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res. 2012;18(5):1341–51.CrossRef Azim HA Jr, et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res. 2012;18(5):1341–51.CrossRef
27.
go back to reference Anderson WF, et al. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 2009;28(2):232–9.CrossRef Anderson WF, et al. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 2009;28(2):232–9.CrossRef
28.
go back to reference Alemayehu M, Meskele M. Health care decision making autonomy of women from rural districts of southern Ethiopia: a community based cross-sectional study. Int J Women's Health. 2017;9:213–21.CrossRef Alemayehu M, Meskele M. Health care decision making autonomy of women from rural districts of southern Ethiopia: a community based cross-sectional study. Int J Women's Health. 2017;9:213–21.CrossRef
29.
go back to reference Ndom P, et al. A meta-analysis of male breast cancer in Africa. Breast. 2012;21(3):237–41.CrossRef Ndom P, et al. A meta-analysis of male breast cancer in Africa. Breast. 2012;21(3):237–41.CrossRef
30.
go back to reference Mbonde M, et al. Expression of oestrogen and progesterone receptors, Ki-67, p53 and BCL-2 proteins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African population. East Afr Med J. 2001;78(7):360–5.CrossRef Mbonde M, et al. Expression of oestrogen and progesterone receptors, Ki-67, p53 and BCL-2 proteins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African population. East Afr Med J. 2001;78(7):360–5.CrossRef
31.
go back to reference Mousa SM, et al. Patterns of seeking medical care among Egyptian breast cancer patients: relationship to late-stage presentation. Breast. 2011;20(6):555–61.CrossRef Mousa SM, et al. Patterns of seeking medical care among Egyptian breast cancer patients: relationship to late-stage presentation. Breast. 2011;20(6):555–61.CrossRef
32.
go back to reference Gakwaya A, et al. Cancer of the breast: 5-year survival in a tertiary hospital in Uganda. Br J Cancer. 2008;99(1):63.CrossRef Gakwaya A, et al. Cancer of the breast: 5-year survival in a tertiary hospital in Uganda. Br J Cancer. 2008;99(1):63.CrossRef
33.
go back to reference Caplan L. Delay in breast cancer: implications for stage at diagnosis and survival. Front Public Health. 2014;2:87.CrossRef Caplan L. Delay in breast cancer: implications for stage at diagnosis and survival. Front Public Health. 2014;2:87.CrossRef
34.
go back to reference Weiner CM, et al. Characteristics and follow-up of metastatic breast cancer in Ethiopia: a cohort study of 573 women. Breast. 2018;42:23–30.CrossRef Weiner CM, et al. Characteristics and follow-up of metastatic breast cancer in Ethiopia: a cohort study of 573 women. Breast. 2018;42:23–30.CrossRef
35.
go back to reference Ferlay J, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.CrossRef Ferlay J, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.CrossRef
36.
go back to reference Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5). Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5).
37.
go back to reference Donepudi M, et al. Breast cancer statistics and markers. J Cancer Res Ther. 2014;10(3):506–11.PubMed Donepudi M, et al. Breast cancer statistics and markers. J Cancer Res Ther. 2014;10(3):506–11.PubMed
38.
go back to reference Torre LA, et al. Global Cancer incidence and mortality rates and trends—an update. Cancer Epidemiology Biomarkers & Prevention. 2016;25(1):16–27.CrossRef Torre LA, et al. Global Cancer incidence and mortality rates and trends—an update. Cancer Epidemiology Biomarkers & Prevention. 2016;25(1):16–27.CrossRef
39.
go back to reference Coleman MP, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). The lancet oncology. 2008;9(8):730–56.CrossRef Coleman MP, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). The lancet oncology. 2008;9(8):730–56.CrossRef
40.
go back to reference Pace LE, Shulman LN. Breast cancer in sub-Saharan Africa: challenges and opportunities to reduce mortality. Oncologist. 2016;21(6):739–44.CrossRef Pace LE, Shulman LN. Breast cancer in sub-Saharan Africa: challenges and opportunities to reduce mortality. Oncologist. 2016;21(6):739–44.CrossRef
Metadata
Title
Breast cancer care in northern Ethiopia – cross-sectional analysis
Authors
Biniyam Tefera Deressa
Nikola Cihoric
Eugenia Vlaskou Badra
Alexandros Tsikkinis
Daniel Rauch
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5612-6

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine